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Abstract Switching from intravenous to oral antibiotic ther-
apy may improve inpatient management and reduce hospital
stays and the complications of intravenous treatment. We
aimed to assess the effectiveness of intravenous-to-oral anti-
biotic switch therapy and an early discharge algorithm in hos-
pitalized patients with gram-positive infection. We performed
a prospective cohort study with a retrospective comparison
cohort, recruited from eight tertiary, acute-care Spanish refer-
ral hospitals. All patients included had culture-confirmed
methicillin-resistant gram-positive infection, or methicillin-
susceptible gram-positive infection and beta-lactam allergy
and had received intravenous treatment with glycopeptides,
lipopeptides, or linezolid. The study comprised two cohorts:
the prospective cohort to assess the effectiveness of a sequen-
tial intravenous-to-oral antibiotic switch algorithm and early
discharge, and a retrospective cohort in which the algorithm
had not been applied, used as the comparator. A total of 247
evaluable patients were included; 115 in the prospective and
132 in the retrospective cohort. Forty-five retrospective pa-
tients (34 %) were not changed to oral antibiotics, and 87
(66 %) were changed to oral antibiotics without following
the proposed algorithm. The duration of hospitalization was
significantly shorter in the prospective cohort compared to the
retrospective group that did not switch to oral drugs (16.7
± 18.7 vs 23±13.4 days, P < 0.001). No differences were
observed regarding the incidence of catheter-related
bacteraemia (4.4 % vs 2.6 %, P=0.621). Our results suggest
that an intravenous-to-oral antibiotic switch strategy is effec-
tive for reducing the length of hospital stay in selected hospi-
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Introduction
The rising incidence of infections caused by methicillin-
resistant gram-positive microorganisms has increased the
use of glycopeptide and lipopeptide antibiotics, and li-
nezolid [1–7]. However, glycopeptides and lipopeptides
have the disadvantage of requiring intravenous (IV) ad-
ministration, which often involves prolonged hospitaliza-
tion and carries a risk of catheter-related complications.
Several studies have demonstrated the efficacy and
safety of switching from intravenous to oral antibiotics
in clinically stable patients [8–19]. Intravenous-to-oral
switch therapy facilitates hospital discharge while
maintaining equivalent outcomes; therefore, it can be
an effective approach to improve inpatient management
and reduce the risk and cost associated with prolonged
hospital stays and catheter-related adverse events [9,
14, 16, 17, 20]. Other potential benefits include in-
creased patient satisfaction, and a reduction in potential
reservoirs of methicillin-resistant gram-positive micro-
organisms in the hospital, thereby lowering the likeli-
hood of transmission to uncolonized patients and med-
ical staff. However, although sequential intravenous-to-
oral therapy is becoming an increasingly more widely
used strategy, many patients still remain hospitalized
under IV treatment until their infection resolves.
Proper patient selection, patient health education,
and an active therapeutic approach by multidisciplinary
medical teams are the key factors leading to success in
conversion from intravenous to oral antimicrobials [9,
21]. Daily patient evaluation by an infectious disease
specialist has a significant impact on antimicrobial use,
facilitating intravenous-to-oral switch and identifying
patients who may be suitable for early discharge [22].
The objective of this study was to assess the effectiveness
of actively applying an algorithm for intravenous-to-oral anti-
biotic switch therapy and early discharge in the management
of hospitalized patients with gram-positive infections requir-
ing treatment with glycopeptides, lipopeptides, or linezolid.
Material and methods
This is a prospective cohort study with a retrospective
historical comparison cohort, recruited from eight
Spanish tertiary referral hospitals. The study includes
hospitalized adult patients (older than 17 years) with a
culture-confirmed diagnosis of methicillin-resistant
gram-positive infection, or methicillin-susceptible
gram-positive infection and beta-lactam allergy, who
received IV treatment with glycopeptides, lipopeptides,
or linezolid. The primary endpoint was the reduction in
the length of hospital stay from the time point when
gram-positive infection had been diagnosed.
Study design and population
The study comprised two cohorts: a retrospective co-
hort (July 2010 to December 2011) in which the
switch therapy algorithm was not applied, used as the
comparison group, and a prospective cohort to assess
the effectiveness of the proposed algorithm over a 1-
month follow-up once antimicrobial treatment had been
completed (January 2012 to September 2014).
Physicians trained in antibiotic management (infectious
disease or internal medicine staff) evaluated all patients
included in both cohorts.
In the retrospective comparison group, pharmacy re-
cords were used to identify patients who had been
p r e s c r i b ed IV t r e a tmen t w i t h g lycopep t i d e s ,
lipopeptides, or linezolid for more than 72 h. The pa-
tients were evaluated by the researchers at each centre,
and those with a culture-confirmed diagnosis of gram-
positive infection who met all the inclusion and none
of the exclusion criteria were enrolled in the study.
In the prospective cohort, daily microbiology and/or
pharmacy antibiotic reports were used to identify po-
tential candidates for inclusion among hospitalized pa-
tients with a confirmed gram-positive infection. The
patient’s suitability for enrolment was formally
assessed by us ing an a lgor i thm des igned for
intravenous-to-oral antibiotic switch therapy and early
discharge (Fig. 1). The inclusion criteria for changing
from intravenous-to-oral were improvements in the in-
fection, resolution of fever, hemodynamic stability
(systolic blood pressure of ≥ 100 mmHg and no unex-
plained tachycardia defined as heart rate greater than
100 beats per minute in last 12 h), progressive reduc-
tions in white blood cell count, and absence of a com-
plex infection requiring treatment on an inpatient basis
(e.g., meningitis, endocarditis). The exclusion criteria
were age younger than 18 years, intensive care unit
admission at the time of the first evaluation, presence
of a non-drained abscess of more than 3 cm, reason-
able concerns about potential patient compliance, pa-
tient unable to take oral therapy, and refusal to partic-
ipate. Patients who met all these conditions and signed
the informed consent to participate were included in
the prospective cohort study. All patients included in
the prospective cohort were evaluated according to the
following schedule of visits: an initial screening visit
(to recruit the patient), daily monitoring visits during
hospitalization (first to assess the intravenous-to-oral
switch and thereafter to assess the possibility of dis-
charge), and a final study visit at 1 month after the
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antibiotic schedule had been completed. In addition to the
study visits by the researchers, all prospective patients were
visited by their attending physicians, who conducted clinical
monitoring for as long as was considered necessary to confirm
resolution of the patient’s condition. The SEQUENCE study
was approved by the Hospital Universitari Vall d’Hebron
Institutional Review Board (code HVH-ATB-2010-01).
Study variables and data collection
The demographic, clinical, laboratory, and microbiological
data and the patient’s clinical course and outcome were re-
corded retrospectively in the retrospective cohort and prospec-
tively in the prospective one. The incidence of catheter-related
infection was recorded in both cohorts. All data were anony-
mously entered into a dedicated database for analysis.
Definitions
Early intravenous-to-oral antibiotic switch therapy was de-
fined as a switch occurring within 5 days after the start of IV
therapy. We chose a 5-day interval, considering that it was the
period of time necessary to have all the microbiological data,
including, in the case of bacteraemia, the result of control
blood cultures obtained within 72 h after starting directed
antibiotic treatment. Failure of the proposed algorithm was
established on infection-related patient death, need for read-
mission due to the infectious process, or need to change back
to IV treatment because the patient showed no improvement.
Early hospital discharge was defined as discharge within 48 h
after the switch.
Statistical analysis
Continuous variables were compared using the Mann–
Whitney U test, and are expressed as the mean and standard
deviation (SD) or the median and interquartile range (IQR).
Categorical variables were compared using the chi-square test
or Fisher's exact test. Data were analysed using SPSS
(Statistical Package for the Social Sciences) software (version
18.0). All analyses were 2-tailed, and a P value <0.05 was
considered statistically significant.
Fig. 1 Algorithm for intravenous-to-oral switch therapy and early discharge
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Results
A total of 247 evaluable patients, 142 (57.5 %) men,
with a median age of 70 years (57–80) were included:
132 patients were in the retrospective group, which
comprised 45 (34 %) who did not switch to oral anti-
biotics and 87 (66 %) who switched without following
the proposed algorithm, and 115 patients were in the
prospective cohort (Fig. 2). Patients in the retrospective
cohort who had been converted to oral antibiotic treat-
ment without following the proposed algorithm were
mainly affected with osteoarticular infection (32 of 34
cases, 94 %), skin and soft tissue infection (16 of 22,
73 %), respiratory infection (nine of 14, 65 %), and
urinary infection (12 of 20, 60 %). The change to oral
therapy was used the least in patients with catheter-
related infection (seven of 22, 32 %). Length of hospital
stay from the diagnosis of gram-positive infection was
shorter in patients receiving oral continuation therapy
than in those not receiving it (16.9 ± 11.0 days vs 30.6
± 53.0; P= 0.003).
The prospective patients (N=115) were compared with the
patients in the retrospective cohort who did not change to oral
antibiotics (N=45) (Table 1). The two groups were compara-
ble for age (66.1±16.2 vs 69.2±16.9 years, P=0.221), sex
(male, 55.7 % vs 60.0 %, P=0.723), and hospitalization re-
quirement in the previous 6 months (61, 53.0% vs 21, 46.7%,
P=0.487). The retrospective cohort included a higher per-
centage of bloodstream infections (26, 57.8 % vs 16,
17.6 %, P < 0.001) and catheter-related infections (15,
33.3 % vs 5, 4.3 %, P< 0.001), but fewer osteoarticular
infections (2, 4.4 % vs 71, 61.7 %, P<0.001). With regard
to catheter-related infections, four of the five prospective pa-
tients with a catheter-related infection were successfully
changed to oral linezolid. Intravenous antibiotic was adminis-
tered for a longer period in retrospective patients than in pro-
spective ones (mean duration of IVantibiotics 14±9.3 vs 7.8
±4.5 days, P<0.001). All patients in the prospective group
were switched to oral continuation antimicrobial therapy with
one or more of the following that antibiotics: linezolid 63
(55 %), cotrimoxazole 38 (33 %), levofloxacin 14 (12 %),
and clindamycin 11 (9.5 %). In 48 patients (42 %) with an
osteoarticular infection, rifampin was co-administered as a
part of their oral antibiotic regimen.
Outcome analysis
Only 59 prospective patients (51 %) were afforded an
early discharge. Nonetheless, there was reduction in the
length of hospital stay in prospective patients compared
to the retrospective cohort (16.7 ± 18.7 vs 23.0
± 13.4 days, P< 0.001). Only five episodes of catheter-
related infection related to the treatment were detected,
with no differences between the two cohorts (3, 2.6 %
vs 2, 4.4 % P= 0.621). The proposed switch algorithm
failed in ten prospective patients (8.7 %). Eight patients
required readmission due to failure to improve in seven
patients and a related adverse effect (Clostridium
difficile infection) in one patient (Table 2). One patient
who had been switched to oral rifampin plus linezolid
required a change back to IV antibiotic due to gastroin-
testinal intolerance, and one patient with a methicillin-
Fig. 2 Patients included in the
study
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resistant S. aureus respiratory infection died due to pro-
gression of the infection and respiratory failure. One
patient in the retrospective cohort also died because of
progression of the infection.
Of part icular note, 32 of the 34 patients with
osteoarticular infection in the retrospective cohort had
been switched to oral antibiotics without following the
proposed algorithm, and for that reason, were excluded
from the main comparative analysis. Therefore, we per-
formed two different sub-analyses to enable comparability
between the two cohorts. First, we analysed the length of
hospital stay excluding all patients with osteoarticular in-
fection in both cohorts, which left 43 retrospective patients
and 44 prospective ones for the comparative analysis. The
reduction in hospital stay in the prospective cohort
compared with the retrospective one was confirmed (12.5
± 9.5 vs 21.8 ± 18.1 days, P< 0.001). Second, we compared
all patients with osteoarticular infections sequenced to oral
therapy in the two cohorts (32 retrospective and 71 pro-
spective patients). The time interval from diagnosis of in-
fection to the switch to oral antibiotics was lower in pro-
spective patients (9.2 ± 8.0 vs 12.2 ± 10.1 days, P= 0.006),
although the length of hospitalization did not significantly
differ (19.2 ± 13.9 vs 21.2 ± 16.3 days, P= 0.183). Only 35
patients (50 %) were afforded an early discharge. The rea-
sons preventing an early discharge were rehabilitation re-
quirements in 15 patients, social reasons (mainly long-term
care facility requirement) in 14 patients, refusal to dis-
charge by the attending physician in four patients, and
uncontrolled co-morbidity in two patients.






Age, years, mean (SD) 69.2 (16.9) 66.1 (16.2) 0.221
Sex, male 27 (60) 64 (55.7) 0.723
Patients hospitalized in previous 6 months 21 (46.7) 61 (53.0) 0.487
Site of infection
Catheter-related infections 15 (33.3) 5 (4.3) <0.001
Urinary tract infections 8 (17.8) 8 (7) <0.074
Skin and soft-tissue infections 6 (13.3) 21 (18.3) 0.639
Respiratory infections 5 (11.1) 4 (3.5) 0.118
Osteoarticular infectionsa 2 (4.4) 71 (61.7) <0.001
Abscess 0 3 (1.9) 0.001
Other infectionsb 9 (20) 3 (2.6) 0.560
Positive blood culture 26 (57.8) 16 (13.9) <0.001
Microbiological aetiologyc
Methicillin-resistant Staphylococcus aureus 15 (33.3) 54 (47) 0.118
Methicillin-susceptible Staphylococcus aureusd 0 4 (3.5) 0.577
Methicillin-resistant coagulase-negative staphylococci 14 (31.1) 44 (38.3) 0.398
Methicillin-susceptible coagulase-negative staphylococcid 3 (6.7) 4 (3.5) 0.375
Ampicillin-resistant Enterococcus faecium 11 (24.4) 10 (8.7) 0.008
Ampicillin-susceptible Enterococcus spp.d 1 (2.2) 3 (2.6) 0.888
Streptococcus pneumoniaed 1 (2.2) 0 0.281
Length of IV antibiotics, days, mean (SD) 14.2 (9.3) 7.8 (4.5) <0.001
Length of hospital stay, days, mean (SD)e 23 (13.4) 16.7 (18.7) <0.001
Treatment catheter-related infection 2 (4.4) 3 (2.6) 0.621
Related mortality 1 (2.2) 1 (0.9) >0.999
Values are expressed as n (%) unless otherwise indicated
a 63 of 73 osteoarticular infections were prosthetic joint infections or osteosynthesis infections, and ten osteoarticular infections were chronic
osteomyelitis
b Other infections include five primary bacteraemia, three peritonitis, two cholangitis, one empyema and one pacemaker-associated infection
c Four patients included in the prospective cohort had polymicrobial infection due to two different gram-positive isolates. Therefore, 119 isolates were
identified in the prospective cohort
d In patients with beta-lactam allergy
e Length of hospital stay from diagnosis of gram-positive infection to hospital discharge or death
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Discussion
The results of this study confirm the effectiveness of an algo-
rithm of intravenous-to-oral antibiotic switch therapy in terms
of reducing the length of hospitalization and duration of intra-
venous antibiotic therapy in all patient according to all the
diagnoses included, with the exception of those with
osteoarticular infection, in whom the length of hospitalization
was comparable in those switching or not.
More than 10 years ago, it was reported that the length of
hospital stay and the duration of IVantibiotic treatment can be
shortened when an early switch policy is introduced once
culture results are known [23]. Nonetheless, few studies to
date have investigated the effectiveness of an intravenous-to-
oral antibiotic switch algorithm. In one randomized study,
50 % of patients initially treated with parenteral antibiotics
had their regimens refined after 3 days of therapy, and these
modifications resulted in good clinical outcomes with a sub-
stantial reduction in antibiotic expenditure [8]. Another study
identified patients likely to be suitable for early discharge as
those with skin or soft-tissue infection, no high-risk comor-
bidities, and less than five other regularly prescribed drugs [9].
It has been also demonstrated that the intervention of an anti-
microbial management team results in earlier intravenous-to-
oral switching and shorter duration of antibiotic therapy, with
the potential for early discharge in some of the patients [22].
Our results are consistent with the findings in these studies.
Even though a reduction in the length of hospital stay was
seen in our series, only 50 % of patients were afforded early
discharge. This indicates that other factors in addition to the
treatment administration route can delay discharge, the most
common ones in our series being social and rehabilitation
requirements.
It is noteworthy that most patients with a catheter-related
infection in the retrospective cohort had not been switched to
an oral antibiotic, and that only five prospective patients had
catheter-related infection. Although intravenous-to-oral anti-
biotic switch therapy is not an established practice in catheter-
related infection, a multicentre comparative study showed that
linezolid is as effective as standard vancomycin therapy when
treating catheter-related bloodstream infections caused by
gram-positive microorganisms [24]. In our series, four of five
catheter-related infections were safely switched to oral linez-
olid once bacteraemia had resolved. This is a small number of
patients, but Wilcox et al. had just published their multicentre
comparative study [24]. Probably because their results were
still little-known, intravenous-to-oral antibiotic switchwas un-
common in patients with catheter-related bacteraemia.
However, based on Wilcox’s results and our experience, we
consider that patients with an uncomplicated catheter-related
gram-positive bacteraemia are a possible target group for ef-
fective oral switch therapy with linezolid.
With regard to orthopaedic infection, intravenous-to-oral
antibiotic switch therapy is established practice in our setting,
as 32 of 34 retrospective patients had been sequenced sponta-
neously by their attending physician without following any
algorithm. Application of an intravenous-to-oral switch algo-
rithm by a specialist enabled earlier switching, but it did not
significantly shorten hospital stay in this subgroup of patients.
Factors such as surgical wound healing and the need for func-
tional rehabilitation are likely the main reasons for continued
hospitalization.
Seven prospective patients who had been switched to oral
antibiotics required hospital readmission and a new intrave-
nous treatment with antibiotics. All these patients (six
osteoarticular infections and one complicated skin infection)
Table 2 Patients in the prospective cohort who required hospital readmission due to the infection and changed back to IVantibiotic treatment






Reason for readmission Comments
1 Knee PJI CONS DAP CLIN+RF C. difficile-associated diarrhoea Antibiotics were not
reintroduced
2 Cellulitis MRSA, GNB VAN+CIP COT+ CIP Persistence of infection Surgical debridement
3 Knee PJIa CONS VAN LIN Persistence of PJI 2-stage removal
4 Chronic
osteomyelitis
CONS TEICO LIN+RF Persistence of infection New surgery
5 Knee PJIa MRSA DAP LIN+RF Persistence of PJI 2-stage removal
6 Shoulder PJIa CONS VAN COT+ RF Persistence of PJI 2-stage removal
7 Chronic
osteomyelitis
CONS TEICO LIN Persistence of infection+GNB
superinfection
New surgery
8 Knee PJI CONS DAP LIN Persistence of infection New surgical approach
PJI prosthetic joint infection, CONS coagulase-negative staphylococci, MRSA methicillin-resistant S. aureus, GNB gram-negative bacilli, MSSA
methicillin-susceptible S. aureus (in patients with beta lactam allergy), DAP daptomycin, CLIN clindamycin, RF rifampicin, VAN vancomycin, CIP
Ciprofloxacin, COT Cotrimoxazole, LIN linezolid, TEICO teicoplanin
a Three patients diagnosed with PJI had been previously treated with debridement, antibiotics, and implant retention, but this strategy failed and all of
them required prosthesis removal using a two-stage approach
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required surgical debridement to resolve the infection, thus
illustrating the importance of an extensive surgical approach
in these conditions.
Finally, we would like to draw your attention to one last
issue. One theoretical benefit of intravenous-to-oral antibiotic
switch therapy is that it can reduce catheter-related adverse
events [20], but we found no differences between prospective
and retrospective patients in the incidence of catheter-related
bacteraemia. Catheter-associated complications are often
underreported in medical charts, and this may partially explain
the low incidence of catheter-related bacteraemia in retrospec-
tive patients. This can be considered a limitation of our study.
Other possible limitations are related to the methods: we
enrolled patients with various infections caused by different
microorganisms which can make comparisons difficult, we
compared a prospective group with a retrospective one in
which certain data were difficult to obtain, and there was some
lack of uniformity between the eight centres included in the
study. However, it had been necessary to include a large num-
ber of patients to perform subgroup analysis, and comparison
with a prospective group in which there were no intervention
with respect to antibiotic treatment could lead to a conflict of
ethics in a situation that is considered beneficial for the patient.
The lack of uniformity can also have a positive side, as it
shows that the intravenous-to-oral algorithm can be effective-
ly used in a variety of clinical settings once candidate patients
have been carefully selected using a systematic approach with
criteria established by consensus.
In conclusion, our data suggest that intravenous-to-oral an-
tibiotic switch therapy is a useful approach for managing select-
ed hospitalized patients with gram-positive infection, as it safe-
ly reduces the length of hospital stay and intravenous treatment.
In patients with osteoarticular infection, the timing of the switch
to oral antibiotics was earlier when our strategy was implement-
ed, but the length of hospital stay did not significantly differ,
probably because other factors, such as surgical wound healing
and rehabilitation requirements, prevent early discharge.
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